ҩѧרҵӢÓ¡ªÒ©Ñ§´Ê»ã(2)

2025-10-29

˫ä·¨double-blind technique ÌìȻҩÎïcrude drugs; natural drugs Ó²¸à¼Áplaster ÓÐЧ°ëË¥ÆÚeffective halt

ÓÐЧÂÊeffective rate ÓÐЧŨ¶Èeffective concentration

ÖÎÁÆÁ¿therapeutic dose ÖÎÁÆÒ©ÎïÁÙ²âtherapeutic drug monitoring; TDM

ÖÎÁÆÖ¸Êýtherapeutic index TI ÖÎÁÆ×÷ÓÃtherapeutic action

ÓÒÐýÌÇdextrose ÓÒÐýÌådextrorotatory form

ãмÁÁ¿threshold dose ÔØÌåcarrier

ÊÜÌ弤¶¯¼Áreceptor stimulant ÊÜÌåÞ׿¹¼Áreceptor antagonist

Íâ¶¾ËØexotoxin ÍâÏûÐýÌåraceme

Ò©Îï·ÖÎöpharmaceutical analysis Ò©Îﻯѧpharmaceutical chemistry Ò©Æ·¸ºÔðÆÚallotted date of drug quality ensuring by manufacturer

Ò©Æ·¹ÜÀí·¨drug administration law Ò©Æ·ÅúºÅdrug batch number

ҩƷʹÓÃÆÚlimit date of using a drug after its production

Ò©Æ·ÓÐЧÆÚexpiry date; date of expiration Ò©Æ·ÖÊÁ¿±ê×¼drug standard ·¢½Ífermentation ·¨¶¨´¦·½official formula

Э¶¨´¦·½cipher prescription Ðò¹áÉè¼Æsequential design

¶àÌÇpolyose ¶àëÄpolypeptide

µç½âelectrolyzation µç½âÖÊelectrolyte

¼¤»î¼Áactivator ¼¤»î×÷ÓÃactivation

¼¤ËØhormone ¼¤ËØÔ­prohormone

ÖмäÌåintermediate ÖúÂ˼Áfilter aid

ÖúÈܼÁcomplex solubilizer ÖúÐü¼Ásuspending agent

×ÔÉíÃâÒßautoimmunity ×é°·histamine

×î´óÄÍÊܼÁÁ¿maximal tolerable dose; LDO ×î´óÎÞ×÷ÓüÁÁ¿maxial noneffective dose; EDO

×îСÏÔÖø²îÊýleast significant difference×ô¼Áadjuvant

×óÐýÌÇlevulose ×óÐýÌålevorotatory form

6-Á×ËáÆÏÌÑÌÇÍÑÇâøglucose-6-phosphate dehydrogenase²»ÍêÈ«¿¹Ô­incomplete antigen

Janbon×ÛºÏÖ¢Janbon's syndrome PPBŨ¶Èparts per billion concentration


ҩѧרҵӢÓ¡ªÒ©Ñ§´Ê»ã(2).doc ½«±¾ÎĵÄWordÎĵµÏÂÔØµ½µçÄÔ ÏÂÔØÊ§°Ü»òÕßÎĵµ²»ÍêÕû£¬ÇëÁªÏµ¿Í·þÈËÔ±½â¾ö£¡

ÏÂһƪ£º¿Õ¼ä¼¸ºÎÌå֪ʶµã¹éÄÉ

Ïà¹ØÔĶÁ
±¾ÀàÅÅÐÐ
¡Á ÓοͿì½ÝÏÂÔØÍ¨µÀ£¨ÏÂÔØºó¿ÉÒÔ×ÔÓɸ´ÖƺÍÅŰ棩

ÏÂÔØ±¾ÎĵµÐèÒªÖ§¸¶ 7 Ôª

Ö§¸¶·½Ê½£º

¿ªÍ¨VIP°üÔ»áÔ± ÌØ¼Û£º29Ôª/ÔÂ

×¢£ºÏÂÔØÎĵµÓпÉÄÜ¡°Ö»ÓÐĿ¼»òÕßÄÚÈݲ»È«¡±µÈÇé¿ö£¬ÇëÏÂÔØÖ®Ç°×¢Òâ±æ±ð£¬Èç¹ûÄúÒѸ¶·ÑÇÒÎÞ·¨ÏÂÔØ»òÄÚÈÝÓÐÎÊÌ⣬ÇëÁªÏµÎÒÃÇЭÖúÄã´¦Àí¡£
΢ÐÅ£ºxuecool-com QQ£º370150219